▎Edited by the WuXi AppTec content teamAccording to incomplete statistics from Innovation Radar, in the two weeks before and after the Spring Festival holiday (January 27 to February 9), the global health sector...A total of 52 financing events were disclosed, with a total amount exceeding 13.6 billion yuan.。In terms of amount, there were 25 financings of 100 million yuan or more.According to the disclosed financing rounds, there were 19 early-stage financings (before Series B) and 16 mid-to-late stage financings (Series B and later). A total of 18 companies in the biopharmaceutical field received financing.Among which, 4 completed IPOs.。
Metsera, Inc. Goes Public on Nasdaq
Keyword: Polypeptide
Latest Financing:Approximately $275 Million IPONews on January 30: Metsera announced its listing on Nasdaq, with total proceeds expected to be approximately $275 million. Metsera is a clinical-stage biopharmaceutical company.Focus on the Development of Nutritional Stimulating Hormone (NuSH) Analog PeptidesMetsera also owns a novel peptide lipidation platform and an oral peptide delivery platform. The novel peptide lipidation platform enables peptides to bind simultaneously with albumin and drug targets, extending the half-life close to that of albumin and 2 to 3 times longer than other NuSH peptides. The oral peptide delivery platform integrates multiple proprietary technologies to deliver therapeutic effects at dose levels significantly lower than competing NuSH oral peptides, unlocking the potential for efficacy and tolerability comparable to injectables.Sionna Therapeutics Goes Public on NASDAQ
Keyword: Small Molecule Drugs
Latest Financing:Approximately $191 Million IPOOn February 6, Sionna Therapeutics, Inc. announced its listing on Nasdaq, with total proceeds expected to be approximately $191 million. Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company with the mission ofRevolutionize the current cystic fibrosis (CF) treatment paradigm by developing novel drugs that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.Sionna’s goal is to provide differentiated drugs for CF patients by directly stabilizing the nucleotide-binding domain 1 (NBD1) of CFTR to restore its CFTR protein function to a level as close to normal as possible. Sionna has demonstrated preclinical data, including data from human bronchial epithelial cell (CFHBE) models, which show that when its NBD1 stabilizer is used in combination with complementary modulators, it can restore the maturation, trafficking, and function of ΔF508-CFTR to wild-type levels.Maze Therapeutics Goes Public on Nasdaq
Keyword: Small Molecule Drugs
Latest Financing:Approximately $140 Million IPOOn February 6, Maze Therapeutics announced its listing on Nasdaq, with total proceeds expected to be approximately $140 million. Maze Therapeutics is a clinical-stage biopharmaceutical company.Leveraging the Power of Human Genetics to Develop Novel Small-Molecule Precision Medicines for Patients with Common Diseases, Focusing on Kidney, Cardiovascular, and Related Metabolic Disorders, Including ObesityIts product pipeline, MZE829, is an oral small-molecule inhibitor developed for patients with APOL1 nephropathy. The Phase 1 clinical trial results published in October 2024 showed that the drug was well-tolerated, and a Phase 2 clinical trial was initiated in November 2024. The first patient dosing is expected to be completed in the first quarter of 2025, with proof-of-concept data anticipated in the first quarter of 2026.Ascentage Pharma Listed on NASDAQ
Keyword: Small Molecule Drugs
Latest Financing:Approximately $126 Million IPOAscentage Pharma announced that the company officially went public on the Nasdaq Global Market on the evening of January 24, with total proceeds expected to be approximately US$126.4 million.Ascentage Pharma is committed to developing innovative drugs in the field of oncology and other therapeutic areas., to address the unmet clinical needs of patients in areas such as oncology. Since its establishment, the company has leveraged its technical expertise in structure-based drug design and its new drug discovery engine. It is committed to developing inhibitors that target key proteins in apoptosis pathways such as Bcl-2 and MDM2-p53, as well as next-generation inhibitors against kinase mutants that arise in cancer treatment, to meet unaddressed medical needs. Currently, Ascentage Pharma has 11 completed or ongoing U.S. and/or international registration studies.AdvanCell Completes $112 Million Series C Financing
Keywords:Radioligand Therapy
MostNew Financing: $112 Million Series C
This round of investment institutions: SV Health Investors, SymBiosis, Tenmile, Morningside Ventures, Sanofi Ventures, etc.On February 3, AdvanCell announced the successful completion of its oversubscribed $112 million Series C financing. This funding will enable AdvanCell to further expand its production capacity.Accelerate the clinical development of its radioligand therapy pipeline.Currently, AdvanCell is recruiting patients with metastatic prostate cancer for the highest dose group in the phase 1/2 clinical trial TheraPb. The trial aims to evaluate the safety and efficacy of the investigational therapy ADVC001. ADVC001 is a potential "best-in-class" radioligand therapy that delivers the alpha particle-emitting isotope lead-212 through a ligand targeting prostate-specific membrane antigen (PSMA).Atalanta Completes $97 Million Series B Financing
Keywords:RNAi
MostNew Financing:$97 Million Series B
This round of investment institutions: EQT Life Sciences, F-Prime Capital, GHR Foundation, Novartis Venture Fund, Sanofi Ventures, etc.On January 28, Atalanta Therapeutics announced the completion of a $97 million Series B financing toSupporting the Phase 1 clinical trial of the company's RNAi drugs for KCNT1-related epilepsy and Huntington's diseaseThe company's unique and innovative di-siRNA drug design has demonstrated widespread distribution in the brain and spinal cord, as well as significant persistence in the brain during preclinical studies. A single administration of di-siRNA showed gene silencing potential lasting 6 months or longer, which may allow for once or twice yearly dosing in a clinical setting.Atalanta Therapeutics' R&D pipeline includes multiple RNAi therapies for treating central nervous system diseases.Among them, ATL-201 is a therapy under research for the treatment of KCNT1-related epilepsy.Aimed at reducing KCNT1 levels and normalizing neuronal excitability.Preclinical studies show that ATL-201 significantly reduces seizures and improves behavior, with good durability and tolerability.Helicore Completes $65 Million Series A Financing
Keywords:GIP Antagonist
MostNew Financing:$65 Million Series A
This round of investment institutions:Versant Ventures, OrbiMedOn January 28, Helicore Biopharma announced its emergence from stealth mode and the completion of a $65 million Series A financing round.Helicore Company Focuses on Developing Potential"First-in-class" Glucose-Dependent Insulinotropic Polypeptide (GIP) Antagonist for the Treatment of Obesity and Related Health IssuesIts leading candidate therapy in terms of R&D progress, HCR-188, is an anti-GIP monoclonal antibody currently in clinical development. HCR-188, when used in combination with GLP-1 drugs, has shown in preclinical studies to preferentially reduce fat rather than lean mass in animals. Compared to GLP-1 drugs alone, it may offer higher-quality weight loss. The company’s pipeline also includes GIP-targeting antibody-drug conjugates, GLP-1 drugs, and combination therapies, designed to target specific subpopulations of obese patients.Auron Completes $27 Million Series B Financing
Keywords: Protein Degradation Therapy
MostNew Financing:$27 Million Series B
This round of investment institutions:Casdin Capital, Data Collective Bio, Franklin Berger, Mubadala Capital, Qiming Venture Partners (US), etc.On February 4, Auron Therapeutics announced the completion of a $27 million Series B financing. The funds obtained from the financingWill be used to advance the Phase 1 clinical proof-of-concept trial of AUTX-703 in patients with acute myeloid leukemia (AML), the trial will begin patient recruitment in the first quarter of this year. AUTX-703 is a potential “first-in-class” oral KAT2A/B protein degrader, discovered and developed by Auron through its AURIGIN platform. Additionally, part of the funding will be used to evaluate the potential of targeting KAT2A/B in the treatment of autoimmune diseases and to advance drug discovery efforts using the company's proprietary AURIGIN platform against epithelial-mesenchymal transition (EMT) cancer targets.Readers, please star ⭐Chuangjianhui to receive push notifications第一时间收到推送.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.
Copyright Statement: This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media platforms, but unauthorized reprints or reproductions by media or institutions in any form to other platforms are strictly prohibited. For reprint authorization, please contact"Innovation Insight"Contact us by leaving a message on our WeChat Official Account.
More Data Content RecommendedClick "InSee", Sharing New Health Trends from Creatheon
